These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14746195)

  • 41. Hormone replacement therapy: the right choice for your patient?
    Leong SL; Erickson DR; Pees RC
    J Fam Pract; 2005 May; 54(5):428-36. PubMed ID: 15865901
    [No Abstract]   [Full Text] [Related]  

  • 42. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 43. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Testosterone replacement therapy: is it worth the risk?
    Zurlinden J
    Nurs Spectr (Wash D C); 1999 Jun; 9(12):15-6. PubMed ID: 10562231
    [No Abstract]   [Full Text] [Related]  

  • 45. I stopped taking hormone replacement therapy a year and a half ago after reports that there might be health risks associated with it. Now that I've been off hormones, do my health risks improve?
    Mayo Clin Health Lett; 2004 Aug; 22(8):8. PubMed ID: 15534954
    [No Abstract]   [Full Text] [Related]  

  • 46. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Breast cancer and the use of the hormones around the menopause].
    Mourits MJ; van der Zee AG
    Ned Tijdschr Geneeskd; 2004 Jan; 148(2):108; author reply 108-9. PubMed ID: 14753135
    [No Abstract]   [Full Text] [Related]  

  • 48. Hormone replacement therapy: the debate should continue.
    Bluming AZ
    Geriatrics; 2004 Nov; 59(11):30-1, 35-7. PubMed ID: 15615158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer risk in the WHI study: the problem of obesity.
    Kuhl H
    Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Estrogen and the skin.
    Murase JE; Wu JJ; Weinstein GD
    J Am Acad Dermatol; 2006 Dec; 55(6):1115-6. PubMed ID: 17110232
    [No Abstract]   [Full Text] [Related]  

  • 51. [Hormone replacement therapy in menopause: (not) a cure all medication].
    Habermann-Horstmeier L
    Pflege Z; 2005 Jul; 58(7):422-4. PubMed ID: 16106827
    [No Abstract]   [Full Text] [Related]  

  • 52. [Hormone therapy and cancer].
    Halse SA
    Ugeskr Laeger; 2004 Feb; 166(8):719; author reply 719-21. PubMed ID: 15042826
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hormone therapy and cancer 2].
    Halse SA
    Ugeskr Laeger; 2004 Mar; 166(12):1133. PubMed ID: 15067781
    [No Abstract]   [Full Text] [Related]  

  • 54. [Hormonal treatment for menopause and arterial risk].
    Gueyffier F; Cornu C
    Rev Prat; 2005 Feb; 55(4):383-8. PubMed ID: 15828616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone replacement therapy use and variations in the risk of breast cancer.
    Opatrny L; Dell'Aniello S; Assouline S; Suissa S
    BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-dose tamoxifen for combination hormone replacement therapy users.
    Fabian CJ
    J Clin Oncol; 2007 Sep; 25(27):4162-4. PubMed ID: 17709795
    [No Abstract]   [Full Text] [Related]  

  • 58. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.
    Feeman W
    Circulation; 2002 Mar; 105(12):e71. PubMed ID: 11915890
    [No Abstract]   [Full Text] [Related]  

  • 59. DNA microarray-based analysis of single nucleotide polymorphisms may be useful for assessing the risks and benefits of hormone therapy.
    Tempfer CB; Riener EK; Hefler LA; Huber JC; Muendlein A
    Fertil Steril; 2004 Jul; 82(1):132-7. PubMed ID: 15237001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone therapy: a dangerous elixir?
    Pearson H
    Nature; 2004 Sep; 431(7008):500-1. PubMed ID: 15457228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.